On Friday, Shares of Aetna Inc (NYSE:AET), gained 3.54% to $105.32.
Aetna Inc., declared a quarterly cash dividend of $0.25 per share on the company’s common stock. The dividend is payable on January 29, 2016, to shareholders of record at the close of business on January 14, 2016.
Declaration and payment of future quarterly dividends is at the discretion of the Board and may be adjusted as business needs or market conditions change.
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit administration services, dental, behavioral health, and vision plans on an insured basis, and an employer-funded or administrative basis.
Shares of Duke Energy Corp (NYSE:DUK), inclined 1.21% to $67.04, during its last trading session.
Grid Assurance, filed its second petition with the Federal Energy Regulatory Commission (FERC) seeking additional declarations that will provide regulatory clarity to further enable transmission-owning entities to take part in and subscribe to the service to strengthen transmission grid resiliency.
Eight electric utilities and energy companies declared June 10 that they had signed a memorandum of understanding to pursue development of Grid Assurance™, a limited liability company that anticipates to offer subscribers cost-effective solutions for enhancing transmission grid resiliency and protecting customers from prolonged transmission outages. In an Aug. 7 order, FERC recognized the benefits of Grid Assurance™. The consortium has since developed a Subscription Agreement and now is seeking additional regulatory clarity from FERC to enable broader transmission owner participation.
Duke Energy Corporation, together with its auxiliaries, operates as an energy company in the United States and Latin America. It operates through three segments: Regulated Utilities, International Energy, and Commercial Power.
Finally, Shares of Baxalta Inc (NYSE:BXLT), ended its last trade with 2.31% gain, and closed at $35.83.
Baxalta Incorporated, declared the official opening of its Global Innovation Center in Cambridge, Massachusetts. The Center is located in Kendall Square at 650 East Kendall Street and will act as the innovation hub of the company’s global infrastructure designed to effectively deliver advanced treatments to patients.
“We are honored to join this robust biotech community in Cambridge,” said John Orloff, M.D., head of Research & Development and chief scientific officer, Baxalta. “Kendall Square was a natural choice for the location of our Global Innovation Center. Here we are surrounded by some of the top minds in the industry, immersed in a biotech community that is unparalleled by any other in the world. Our aim is to become a leading development powerhouse to deliver innovative treatments for patients with unmet medical needs.”
Baxalta’s innovation efforts are focused on the development of lifesaving therapies in hematology, immunology and oncology. The company’s approach to expanding its pipeline is based on an external innovation model, sourcing compounds externally through in-licensing or acquisitions. The Cambridge life science community will provide Baxalta access to a range of innovations and partnership partners with complementary expertise to advance new treatments for patients.
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.